

10<sup>th</sup> August, 2022

To  
The Corporate Relations Department  
BSE Limited  
Phiroz Jeejeebhoy Towers, 25th Floor,  
Dalal Street,  
Mumbai- 400001  
**Scrip Code** - 543308  
**ISIN: INE967H01017**

To  
The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400 051  
**Symbol** - KIMS  
**ISIN: INE967H01017**

Dear Sir

Sub: Outcome of Board Meeting held on 10th August 2022 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our intimations dated 02<sup>nd</sup> August 2022, the Board of Directors, at its meeting held today, has approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the 01<sup>st</sup> Quarter ended 30<sup>th</sup> June 2022 together with Limited Review Reports which has been reviewed by the Audit Committee and approved by the Board of Directors.

The financial results are also available on the website of the Company at <https://www.kimshospitals.com/investors/Disclosures> under Regulation 46 of SEBI (LODR) Regulations, 2015/ [Financial Information/ Financial Result](#) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. [www.bseindia.com](http://www.bseindia.com) and [www.nscindia.com](http://www.nscindia.com), respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 02.00 PM and concluded at ...04:15 PM....


This is for your information and records.

Thanking you,

For Krishna Institute of Medical Sciences Limited



**Umashankar Mantha**  
**Company Secretary & Compliance Officer**  
Encl: As above



**Krishna Institute of Medical Sciences Limited**  
Minister Road, Secunderabad - 500 003, Telangana, India  
Phone: +91-40-4488 5000/4488 5184 | Fax: +91-40-27840980 | [kimshospitals.com](http://kimshospitals.com)  
CIN: L55101TG1973PLC040558

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.no.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital (Bengaluru) Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	Rajyalakshmi Healthcare Private Limited	Step Subsidiary
12	Suryateja Healthcare Private Limited	Step Subsidiary



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## **Other Matter**

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil, total net loss after tax of Rs. 11.98 million, total comprehensive income of Rs. 11.98 million, for the quarter ended June 30, 2022, as considered in the Statement which have been reviewed by their respective independent auditors.


The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

  
per Navneet Rai Kabra

Partner

Membership No.: 102328



UDIN: 22102328AORVMW4002


Place : Hyderabad

Date : August 10, 2022

**Statement of Unaudited Consolidated Financial Results for the Quarter ended 30 June 2022**

(Rupees in millions)

	Quarter Ended			Year ended
	30-Jun-22 (Unaudited)	31-Mar-22 (Audited) Refer Note 2	30-Jun-21 (Unaudited)	31-Mar-22 (Audited)
<b>1 Income</b>				
(a) Revenue from operations	4,955.14	3,723.38	4,731.79	16,508.25
(b) Other income	53.35	81.89	42.73	202.60
<b>Total Income</b>	<b>5,008.49</b>	<b>3,805.27</b>	<b>4,774.52</b>	<b>16,710.85</b>
<b>2 Expenses</b>				
(a) Purchase of medical consumables, drugs and surgical instruments	1,126.91	785.28	1,193.02	3,674.97
(b) Increase in inventories of medical consumables, drugs and surgical instruments	(29.23)	(34.11)	(69.60)	(123.42)
(c) Employee benefits expense	853.10	648.51	725.13	2,619.08
(d) Other expenses	1,652.73	1,187.89	1,446.56	5,179.73
(e) Finance cost	57.26	38.59	63.22	160.33
(f) Depreciation and amortisation expense	294.17	186.37	170.88	726.73
<b>Total Expenses</b>	<b>3,934.94</b>	<b>2,812.53</b>	<b>3,529.21</b>	<b>12,237.42</b>
<b>3 Profit before share of profit from Joint Venture and tax (1-2)</b>	<b>1,073.55</b>	<b>992.74</b>	<b>1,245.31</b>	<b>4,473.43</b>
<b>4 Share of profit from Joint Venture, net of tax</b>	-	75.44	-	95.10
<b>5 Profit before tax (3+4)</b>	<b>1,073.55</b>	<b>1,068.18</b>	<b>1,245.31</b>	<b>4,568.53</b>
<b>6 Tax expense</b>				
(a) Current tax	261.24	226.52	338.07	1,141.55
(b) Deferred tax	19.86	21.05	(13.06)	1.66
(c) Adjustment of tax relating to earlier periods/years	-	(12.63)	-	(12.63)
<b>Total tax expenses (6)</b>	<b>281.10</b>	<b>234.94</b>	<b>325.01</b>	<b>1,130.58</b>
<b>7 Net profit for the period/year (5-6)</b>	<b>792.45</b>	<b>833.24</b>	<b>920.30</b>	<b>3,437.95</b>
Attributable to:				
Owners of the company	699.58	806.88	891.05	3,326.85
Non controlling interests	92.87	26.36	29.25	111.10
<b>8 Other comprehensive income for the period/year</b>				
Items that will not be reclassified subsequently to statement of profit and loss				
- Re-measurement gain/(loss) on defined benefit plans	3.64	18.01	(1.47)	1.53
- Income tax effect	(0.90)	(4.54)	0.38	(0.33)
<b>Other comprehensive income, net of tax</b>	<b>2.74</b>	<b>13.47</b>	<b>(1.09)</b>	<b>1.20</b>
Attributable to:				
Owners of the company	1.60	13.00	(1.19)	1.40
Non controlling interests	1.14	0.47	0.10	(0.20)
<b>9 Total comprehensive income (7+8)</b>				
Owners of the company	701.18	819.88	889.86	3,328.25
Non controlling interests	94.01	26.83	29.35	110.90
<b>Total comprehensive income</b>	<b>795.19</b>	<b>846.71</b>	<b>919.21</b>	<b>3,439.15</b>
<b>10 Paid up equity share capital (face value of Rs.10 each)</b>				800.28
<b>11 Other Equity</b>				13,072.81
<b>12 Earnings per share (of Rs.10 each): (not annualised for the quarter ended)</b>				
(a) Basic (Rs.)	8.74	10.08	11.48	41.88
(b) Diluted (Rs.)	8.74	10.08	11.48	41.88




*M. Manu*

**Notes:**


- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2022 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2022 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Consolidated figures for the quarter ended 31 March 2022 are the balancing figure between the audited consolidated figures in respect of the full financial year 2021-22 and the published unaudited year to date consolidated figures up to the third quarter of the previous financial year 2021-22.
- 3 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 5 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 6 During the current quarter, the Company has completed acquisition of 51.07% of the equity share capital of the Sarvejana Healthcare Private Limited ('Sunshine Hospitals') for a total cash consideration of Rs. 3,627.71 Mn and Sunshine Hospitals has become a subsidiary. The transaction was accounted in accordance with Ind AS 103 - Business Combinations ("Ind AS 103") and the initial accounting was provisionally determined as at 30 June 2022.
- 7 Subsequent to the current quarter, the Company acquired 51.00% of the equity shares of the KIMS Manavatha Hospital Private Limited ('KIMS Manavatha') and KIMS Manavatha has become a subsidiary.
- 8 The previous periods/years numbers have been regrouped/rearranged wherever necessary to conform the current period/year presentation.
- 9 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited



  
Dr. B Bhaskara Rao  
Managing Director  
DIN: 00008985


Hyderabad  
10 August 2022



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP  
Chartered Accountants  
ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra  
Partner  
Membership No.: 102328




UDIN: 22102328AORUWA7675

Place: Hyderabad  
Date: August 10, 2022

**Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2022**

		(Rupees in millions)			
		Quarter Ended			Year ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		(Unaudited)	(Audited) Refer note 2	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>				
	(a) Revenue from operations	2,629.50	2,544.96	3,315.14	11,433.76
	(b) Other income	37.07	77.15	40.17	241.74
	<b>Total Income</b>	<b>2,666.57</b>	<b>2,622.11</b>	<b>3,355.31</b>	<b>11,675.50</b>
<b>2</b>	<b>Expenses</b>				
	(a) Purchase of medical consumables, drugs and surgical instruments	565.86	533.49	864.77	2,594.21
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(4.23)	(22.37)	(55.88)	(95.14)
	(c) Employee benefits expense	473.87	429.18	492.20	1,740.21
	(d) Other expenses	812.70	721.95	903.09	3,232.28
	(e) Finance cost	4.05	5.25	22.49	44.68
	(f) Depreciation and amortisation expense	114.12	113.54	107.36	449.22
	<b>Total Expenses</b>	<b>1,966.37</b>	<b>1,781.04</b>	<b>2,334.03</b>	<b>7,965.46</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>700.20</b>	<b>841.07</b>	<b>1,021.28</b>	<b>3,710.04</b>
<b>4</b>	<b>Tax expense</b>				
	(a) Current tax	177.64	178.25	263.54	909.27
	(b) Deferred tax charge/(credit)	1.34	36.40	(3.88)	29.73
	(c) Adjustment of tax relating to earlier year	-	(12.63)	-	(12.63)
	<b>Total tax expenses</b>	<b>178.98</b>	<b>202.02</b>	<b>259.66</b>	<b>926.37</b>
<b>5</b>	<b>Profit for the period/year (3-4)</b>	<b>521.22</b>	<b>639.05</b>	<b>761.62</b>	<b>2,783.67</b>
<b>6</b>	<b>Other comprehensive income/ (loss)</b>				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement gain/(loss) on defined benefit plans	0.66	16.30	(1.60)	2.63
	- Income tax effect	(0.17)	(4.10)	0.40	(0.66)
	<b>Other comprehensive income/ (loss), net of tax</b>	<b>0.49</b>	<b>12.20</b>	<b>(1.20)</b>	<b>1.97</b>
<b>7</b>	<b>Total comprehensive income (5+6)</b>	<b>521.71</b>	<b>651.25</b>	<b>760.42</b>	<b>2,785.64</b>
<b>8</b>	<b>Paid up equity share capital (face value of Rs.10 each)</b>				800.28
<b>9</b>	<b>Other Equity</b>				12,975.19
<b>10</b>	<b>Earnings per share (of Rs.10 each) : (not annualised for the quarter ended)</b>				
	(a) Basic (Rs.)	6.51	7.99	9.81	35.04
	(b) Diluted (Rs.)	6.51	7.99	9.81	35.04




H. M. M. M.

**Notes:**

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2022 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2022 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The standalone figures for the quarter ended 31 March 2022 are the balancing figure between the audited standalone figures in respect of the full financial year 2021-22 and the published unaudited year to date standalone figures up to the third quarter of the previous financial year 2021-22.
- 3 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 5 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 6 During the current quarter, the Company has completed acquisition of 51.07% of the equity share capital of the Sarvejana Healthcare Private Limited ("Sunshine Hospitals") for a total cash consideration of Rs. 3,627.71 Mn and Sunshine Hospitals has become a subsidiary. The transaction was accounted in accordance with Ind AS 103 - Business Combinations ("Ind AS 103") and the initial accounting was provisionally determined as at 30 June 2022.
- 7 Subsequent to the current quarter, the Company acquired 51.00% of the equity shares of the KIMS Manavatha Hospital Private Limited ("KIMS Manavatha") and KIMS Manavatha has become a subsidiary.
- 8 The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform the current period/year presentation.
- 9 The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited





Dr. B Bhaskara Rao  
Managing Director

DIN: 00008985

Hyderabad  
10 August 2022

